Quality of vision and outcomes after bilateral implantation of pseudo-non diffracting beam IOL.
cataract
extended depth of focus IOL
near vision
premium IOLs
spectacle independence
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
10
2022
accepted:
15
02
2023
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
24
3
2023
Statut:
epublish
Résumé
To analyze the objective and subjective visual performances of a new hybrid refractive/aspheric extended depth of focus (EDOF) intraocular lens (IOL). In this monocentric prospective study patients with bilateral cataracts underwent cataract surgery and were implanted with a Lucidis IOL (SAV-IOL SA, Neuchâtel, Switzerland) in both eyes, 1 week apart from each other. At 3 months from implantation postoperative evaluations included monocular and binocular uncorrected and distance-corrected distant (4 m), intermediate (80 cm, 67 cm) and near (40 cm) visual acuities (UDVA/DCVA, UI80-67VA/DCI80-67VA, UNVA/DCNVA), binocular defocus curves, halometry, contrast sensitivity and objective quality-of-vision measurements. Also, patients were also asked to complete the national eye institute refractive error quality of life (NEI-RQL-42) questionnaire. Twenty-five patients (50 eyes) were included. The mean postoperative binocular UDVA, UI80VA, UI67VA and UNVA were-0.02 ± 0.13, 0.05 ± 0.09, 0.05 ± 0.08 and 0.03 ± 0.1 LogMar, and did not significantly differ from their corrected counterparts. On binocular defocus curves a VA ≥0.05LogMar was found between +0.50 and - 2.50 D of vergence, whereas the mean distance from the central stimulus on halometry was 1.23 ± 0.01. Mean ocular and corneal radical mean square at 4 mm were 0.31 ± 0.28 and 0.19 ± 0.07, respectively; whereas the mean Strehl ratio was 0.2 ± 0.09. Lucidis IOLs demonstrated excellent visual performances, especially at close distances while maintain good quality of vision, contrast sensitivity, and overall patient-satisfaction.
Identifiants
pubmed: 36950509
doi: 10.3389/fmed.2023.1085280
pmc: PMC10025297
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1085280Informations de copyright
Copyright © 2023 Pedrotti, Bonacci, Kilian, Pagnacco, Anastasi, Ventura and Marchini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cataract Refract Surg. 2022 Mar 1;48(3):288-297
pubmed: 34269326
J Refract Surg. 2020 Apr 1;36(4):214-222
pubmed: 32267951
J Cataract Refract Surg. 2015 Nov;41(11):2424-9
pubmed: 26703492
Curr Opin Ophthalmol. 2022 Jan 1;33(1):35-40
pubmed: 34854826
J Cataract Refract Surg. 2011 May;37(5):859-65
pubmed: 21397457
Cochrane Database Syst Rev. 2016 Dec 12;12:CD003169
pubmed: 27943250
BMJ Open Ophthalmol. 2020 Oct 14;5(1):e000497
pubmed: 33083552
Curr Eye Res. 2021 Jun;46(6):811-817
pubmed: 33047991
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2717-2722
pubmed: 34050809
J Refract Surg. 2022 Mar;38(3):158-166
pubmed: 35275002
J Ophthalmol. 2022 May 28;2022:5100861
pubmed: 35669466
Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3357-61
pubmed: 8056510
J Cataract Refract Surg. 2022 Feb 1;48(2):144-150
pubmed: 34653094
Klin Monbl Augenheilkd. 2019 Apr;236(4):384-390
pubmed: 30763956
Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):194-202
pubmed: 32511121
J Refract Surg. 2016 Jul 1;32(7):436-42
pubmed: 27400074
J Cataract Refract Surg. 2015 Nov;41(11):2417-23
pubmed: 26703491
J Cataract Refract Surg. 2008 Aug;34(8):1329-38
pubmed: 18655984
Arch Ophthalmol. 2003 Sep;121(9):1289-96
pubmed: 12963612
Eye Vis (Lond). 2021 Oct 6;8(1):37
pubmed: 34615549
J Cataract Refract Surg. 2020 Feb;46(2):298-304
pubmed: 32126045
PLoS One. 2021 Dec 1;16(12):e0260406
pubmed: 34851975
Br J Ophthalmol. 2008 May;92(5):598-603
pubmed: 18441169